

Integrated Impact Assessment Report for Clinical Commissioning Policies			
Policy Reference Number	1619	1619	
Policy Title	Deep Brain Stimulation for Tourette's	Deep Brain Stimulation for Tourette's	
Lead Commissioner	David Stockdale	Clinical Lead	Thomas Fonteyne
Finance Lead	Jazz Nandra	Analytical Lead	Click here to enter text.

Integrated Impact Assessment – Index			
Section A – Activity	Section B - Service	Section C – Finance	
A1 Current Patient Population & Demography / Growth	B1 Service Organisation	C1 Tariff	
A2 Future Patient Population & Demography	B2 Geography & Access	C2 Average Cost per Patient	
A3 Activity	B3 Implementation	C3 Overall Cost Impact of this Policy to NHS England	
A4 Existing Patient Pathway	B4 Collaborative Commissioning	C4 Overall cost impact of this policy to the NHS as a whole	
A5 Comparator (next best alternative treatment) Patient Pathway		C5 Funding	
A6 New Patient Pathway		C6 Financial Risks Associated with Implementing this Policy	
A7 Treatment Setting		C7 Value for Money	
A8 Coding		C8 Cost Profile	
A9 Monitoring			

## About this Impact Assessment: instructions for completion and explanatory notes

- Each section is divided into themes.
- Each theme sets out a number of questions.
- All questions are answered by selecting a drop down option or including free text.
- Free text boxes are provided to enable succinct relevant commentary to be added which explains the rationale for response or assumption. Please limit responses to 3 sentences of explanatory text.
- Data in this document is either drawn from one of the relevant policy documents or a source for the information is provided.
- Where assumptions are included where data is not available, this is specified.

Section A - Activity Impact		
A1 Current Patient Population & Demography / Growth		
A1.1 Prevalence of the disease/condition.	The policy proposes <b>to not routinely commission</b> the use of deep brain stimulation in treating patients with Tourette's. Approximately, 1% of the population under age 18 has Tourette's Syndrome (Robertson 2008). The majority have mild symptoms and those with a more severe condition generally respond to medication and/or get better spontaneously as they get older, although tics do not usually completely disappear Source: Policy Proposition section 6	
A1.2 Number of patients currently eligible for the treatment according to the proposed policy commissioning criteria.	N/A do not routinely commission proposition  Source: required  Please specify  Click here to enter text.	
A1.3 Age group for which the treatment is proposed according to the policy commissioning criteria.	All ages Please specify Click here to enter text.	
A1.4 Age distribution of the patient population eligible according to the proposed policy commissioning criteria	enter number. if relevant Source: Click here to enter text. Please specify Click here to enter text.	
A1.5 How is the population currently distributed geographically?	Evenly If unevenly, estimate regional distribution by %:	

	North Midlands & East London South	enter % enter %
	Please specify Click here to enter	oposition section 6 r text.
A2 Future Patient Population & Demography		
A2.1 Projected changes in the disease/condition epidemiology, such as incidence or prevalence (prior to applying the new policy) in 2, 5, and 10 years?	Constant  If other, Click here Source: Policy Pro	e to enter text. oposition section 6
A2.2 Are there likely to be changes in demography of the patient population and would this impact on activity/outcomes?	No Please specify Click here to enter text. Source: Policy Proposition section 6/other	
A2.3 Expected net increase or decrease in the number of patients	YR2 +/-	0
who will be eligible for the service, according to the proposed service specification commissioning criteria, per year in years 2-5 and 10?	YR3 +/-	0
	YR4 +/-	0
	YR5 +/-	0
	YR10 +/-	0

	Source: Service specification proposition section 3.1
Are these numbers in line with ONS growth assumptions for the age specific population? If not please justify the growth assumptions made.	Yes Click here to enter text.
A3 Activity	
A3.1 What is the purpose of new policy?	Revise existing policy (expand or restict an existing treatment
	threshold / Add an additiona line of treatment / stage of treatment
	Please specify  The policy is to not reutingly commission the use of deep brain etimulation
	The policy is to not routinely commission the use of deep brain stimulation for the conditions outlined in A1.1.
A3.2 What is the annual activity associated with the existing	0
pathway for the eligible population?	Source: Current DNR published policy
	Please specify
	Click here to enter text.
A3.3 What is the estimated annual activity associated with the	0
proposed policy proposition pathway for the eligible population?	Source: DNR Policy
	Please specify
	Click here to enter text.
A3.4 What is the estimated annual activity associated with the next	Not applicable
best alternative comparator pathway for the eligible population? If	Source: required
the only alternative is the existing pathway, please state 'not	Please specify

applicable' and move to A4.	Click here to enter text.
A4 Existing Patient Pathway	
A4.1 Existing pathway: Describe the relevant currently routinely commissioned:  • Treatment or intervention  • Patient pathway  • Eligibility and/or uptake estimates.	Behavioural therapy is usually the first approach to treatment. If this is unsuccessful medicine may be given; using drugs developed for the treatment of mental health conditions such as psychosis. In some cases muscle relaxing treatments are used.  Source: Policy proposition
A4.2. What are the current treatment access and stopping criteria?	Not applicable Source: required
A4.3 What percentage of the total eligible population is expected to:  a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	If not known, please specify Not applicable as position is to not routinely commission.  a) 0% b) 0% c) 0% d) 0% e) 0% Source: required
A5 Comparator (next best alternative treatment) Patient Pathway  (NB: comparator/next best alternative does not refer to current pathway but to an alternative option)	
A5.1 Next best comparator:	<u>No</u>

Is there another 'next best' alternative treatment which is a relevant comparator?	Not applicable as position is to not routinely commission.
<ul> <li>If yes, describe relevant</li> <li>Treatment or intervention</li> <li>Patient pathway</li> <li>Actual or estimated eligibility and uptake</li> </ul>	If yes, Click here to enter text. Source: PWG
A5.2 What percentage of the total eligible population is estimated to:  a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	Not applicable as position is to not routinely commission.  Total estimated eligible  a) enter % b) enter % c) enter % d) enter % e) enter % Source: Click here to enter text.
A6 New Patient Pathway	
A6.1 What percentage of the total eligible population is expected to:  a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	If not known, please specify N/A Continues do not routinely commission position  a) enter % b) enter % c) enter % d) enter % e) enter % Source: Published Policy

A6.2 Specify the nature and duration of the proposed new treatment or intervention.	One off For time limited treatments, sp Click here to enter text. Source: required	ecify frequ	quency and/or duration.
A7 Treatment Setting			
A7.1 How is this treatment delivered to the patient?	Select all that apply:		
	Emergency/Urgent care atten	ndance	
	Acute Trust: inpatient		
	Acute Trust: day patient		
	Acute Trust: outpatient		
	Mental Health provider: inpati	ient	
	Mental Health provider: outpa	atient	
	Community setting		
	Homecare		
	Other		
	Please specify:	1	
eligible population by region?	<b>NORTH</b> r	number	
	MIDLANDS & EAST r	number	
	<b>LONDON</b> r	number	

	SOUTH	number	<b>&gt;</b>
A7.3 Does the proposition require a change of delivery setting or capacity requirements?	No Please specify: Click here to enter text. Source: DNR Policy		
A8 Coding			
A8.1 Specify the datasets used to record the new patient pathway activity.	Not applicable as position is to	not routinely com	nmission.
	Select all that apply:		
*expected to be populated for all commissioned activity	Aggregate Contract Monitoring	g *	
	Patient level contract monitori	ing	
	Patient level drugs dataset		
	Patient level devices dataset		
<b>&amp;</b> ()	Devices supply chain reconcil	iation dataset	
	Secondary Usage Service (St	JS+)	
	Mental Health Services DataS	Set (MHSDS)	
	National Return**		
	Clinical Database**		
	Other**		
	**If National Return, Clinical da	atabase or other s	elected, please specify:

	Click here to enter text.		
A8.2 Specify how the activity related to the new patient pathway will be identified.	Not applicable as position is to not routinely commission.  Select all that apply:		
	OPCS v4.8		
	ICD10		
	Treatment function code		
	Main Speciality code		
	HRG		
	SNOMED		
	Clinical coding / terming methodology used by clinical profession		
A8.3 Identification Rules for Drugs:	Not applicable		
How are drug costs captured?	: Click here to enter text.		
A8.4 Identification Rules for Devices:	Not applicable		
How are device costs captured?	Click here to enter text.		
	Click here to enter text.		
A8.5 Identification Rules for Activity:	Choose an item.		
How are activity costs captured?	If activity costs are already captured please specify the specialised service code and description (e.g. NCBPS01C Chemotherapy).  Click here to enter text.		

	If activity costs are already captured please specify whether this service needs a separate code. Choose an item.  If the activity is captured but the service line needs amendment please specify whether the proposed amendments have been documented and agreed with the Identification Rules team.  Click here to enter text.  If the activity is not captured please specify whether the proposed identification rules have been documented and agreed with the Identification Rules team. Choose an item.	
A9 Monitoring		
A9.1 Contracts	<u>None</u>	
Specify any new or revised data flow or data collection requirements, needed for inclusion in the NHS Standard Contract Information Schedule.	Please specify Click here to enter text.	
A9.2 Excluded Drugs and Devices (not covered by the Zero	Select all that apply:	
Cost Model)	Drugs or Device MDS	
For treatments which are tariff excluded drugs or devices not covered by the Zero Cost Model, specify the pharmacy or device	Blueteq	
monitoring required, for example reporting or use of prior approval systems.	Other prior approval	
by distinct	Please specify: Not applicable	
A9.3 Business intelligence	<u>No</u>	
Is there potential for duplicate reporting?	If yes, please specify mitigation: Click here to enter text.	

A9.4 Contract monitoring	<u>No</u>
Is this part of routine contract monitoring?	Not applicable as position is to not routinely commission.
	If yes, please specify contract monitoring requirement:
	Click here to enter text.
A9.5 Dashboard reporting	<u>No</u>
Specify whether a dashboard exists for the proposed intervention?	Not applicable as position is to not routinely commission.
	If yes, specify how routine performance monitoring data will be used for dashboard reporting.
	Click here to enter text.
	If no, will one be developed?
	Click here to enter text.
A9.6 NICE reporting	<u>No</u>
Are there any directly applicable NICE or equivalent quality	Not applicable as position is to not routinely commission.
standards which need to be monitored in association with the new policy?	
policy:	If yes, specify how performance monitoring data will be used for this
(· ( )	purpose. Click here to enter text.
	Click here to enter text.
Section B	- Service Impact
B1 Service Organisation	
B1.1 Describe how the service is currently organised? (i.e. tertiary	Tertiary centres
centres, networked provision etc.)	Source: required

B1.2 Will the proposition change the way the commissioned service is organised?  B1.3 Will the proposition require a new approach to the organisation	No Please specify: Click here to enter text. Source: required		
of care?	No change to delivery of car Please specify: Click here to enter text.	are_	
B2 Geography & Access			
B2.1 Where do current referrals come from?	Select all that apply:		
	GP		
	Secondary care		
	Tertiary care		
	Other		
	Please specify:		
	Click here to enter text.		
B2.2 What impact will the new policy have on the sources of	No impact		
referral?	Please specify:		
	Click here to enter text.		
B2.3 Is the new policy likely to improve equity of access?	No impact		
	Please specify:		

	Click here to enter text.  Source: Equalities Impact Assessment
B2.4 Is the new policy likely to improve equality of access and/or outcomes?	No impact Please specify: Click here to enter text. Source: Equalities Impact Assessment
B3 Implementation	
B3.1 Will commissioning or provider action be required before implementation of the proposition can occur?	No action required Please specify: Click here to enter text.
B3.2 <b>Time to implementation:</b> Is a lead-in time required prior to implementation?	No - go to B3.4  If yes, specify the likely time to implementation: Enter text
B3.3 <b>Time to implementation:</b> If lead-in time is required prior to implementation, will an interim plan for implementation be required?	Choose an item.  If yes, outline the plan: Click here to enter text.
B3.4 Is a change in provider physical infrastructure required?	No Please specify: Click here to enter text.
B3.5 Is a change in provider staffing required?	No Please specify:

	Click here to	enter text.		
B3.6 Are there new clinical dependency and/or adjacency requirements that would need to be in place?	No Please specifically Click here to	•		
B3.7 Are there changes in the support services that need to be in place?	No Please specifical Click here to		<b>*</b>	
B3.8 Is there a change in provider and/or inter-provider governance required? (e.g. ODN arrangements / prime contractor)	No Please specif Click here to			
B3.9 Is there likely to be either an increase or decrease in the number of commissioned providers? If yes, specify the current and estimated number of providers required in each region  No change  Not applicable as position is to not routinely commissioned providers.		ission.		
	Region	Current no. of providers	Future State expected	Provisional or
		provide the second	range	confirmed
	North			select
	Midlands & East			select
	London			select
	South			select
			1	1

	Please specify: Click here to enter text.	
B3.10 Specify how revised provision will be secured by NHS	Select all that apply:	
England as the responsible commissioner.	Publication and notification of new policy	$\boxtimes$
	Market intervention required	
	Competitive selection process to secure increase or decrease provider configuration	
	Price-based selection process to maximise cost effectiveness	
	Any qualified provider	
	National Commercial Agreements e.g. drugs, devices	
	Procurement	
	Other	$\boxtimes$
	Please specify: Click here to enter text.	
B4 Place-based Commissioning		
B4.1 Is this service currently subject to, or planned for, place-based commissioning arrangements? (e.g. future CCG lead, devolved commissioning arrangements, STPs)	No Please specify:	
	Click here to enter text.	
Section C	- Finance Impact	

C1 Tariff/Pricing				
C1.1 How is the service contracted and/or charged? Only specify for the relevant section of the patient pathway	Select all that apply:			
	Drugs	Not separately charged – part of local or national tariffs		
		Excluded from tariff – pass through		
		Excluded from tariff - other		
	Devices	Not separately charged – part of local or national tariffs	$\boxtimes$	
		Excluded from tariff (excluding ZCM) – pass through		
		Excluded from tariff (excluding ZCM) – other		
		Via Zero Cost Model		
		Paid entirely by National Tariffs	$\boxtimes$	
		Paid entirely by Local Tariffs		
		Partially paid by National Tariffs		
		Partially paid by Local Tariffs		
		Part/fully paid under a Block arrangement		
		Part/fully paid under Pass-Through arrangements		
		Part/fully paid under Other arrangements		
C4 2 Prove Coata	Not cooling	la la		
C1.2 <b>Drug Costs</b> Where not included in national or local tariffs, list each drug or combination, dosage, quantity, <b>list</b> price including VAT if applicable and any other key information e.g. Chemotherapy Regime.  NB discounted prices or local prices must not be included as these	Not applica	DIE		

are subject to commercial confidentiality and must not be disclosed.	
C1.3 Device Costs	Not applicable as position is to not routinely commission.
Where not included in national or local tariff, list each element of the excluded device, quantity, <b>list or expected</b> price including VAT if applicable and any other key information.	
NB: Discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.	
C1.4 Activity Costs covered by National Tariffs	Not applicable as position is to not routinely commission.
List all the HRG codes, HRG descriptions, national tariffs (excluding MFF), volume and other key costs (e.g. specialist top up %)	
C1.5 Activity Costs covered by Local Tariff	Not applicable
List all the HRGs (if applicable), HRG or local description, estimated average tariff, volume and any other key costs. Also indicate whether the Local Tariff(s) is/are newly proposed or established and if newly proposed how is has been derived, validated and tested.	
C1.6 Other Activity Costs not covered by National or Local Tariff	Not applicable
Include descriptions and estimates of all key costs.	
C1.7 Are there any prior approval mechanisms required either	Choose an item.
during implementation or permanently?	Please specify: Click here to enter text.
C2 Average Cost per Patient	

C2.1 What is the estimated cost per patient to NHS England, in	YR1	£0.00	enter number.	
years 1-5, including follow-up where required?	YR2	£0.00	enter number.	
	YR3	£0.00	enter number.	
	YR4	£0.00	enter number.	
	YR5	£0.00	enter number.	
Are there any changes expected in year 6-10 which would impact the model?  C3 Overall Cost Impact of this Policy to NHS England	If yes, please spe There would be n commission.		the policy is to not	routinely
C3.1 Specify the budget impact of the proposal on NHS England in relation to the relevant pathway.	Cost neutral Please specify:  As the position is  Please specify: Year 1: £0.00 Year 2: £0.00 Year 5: £0.00	to not routinely co	ommission.	

C3.2 If the budget impact on NHS England cannot be identified set	Not Applicable
out the reasons why this cannot be measured.	Tret / tppilodbie
C3.3 If the activity is subject to a change of commissioning responsibility, from CCG to NHS England, has a methodology for the transfer of funds been identified, and calculated?	Not Applicable
C4 Overall cost impact of this policy to the NHS as a whole	
C4.1 Specify the budget impact of the proposal on other parts of the	Budget impact for CCGs:
NHS.	No impact on CCGs
	Budget impact for providers:
	No impact on providers
	Please specify:
	Click here to enter text.
C4.2 Taking into account responses to C3.1 and C4.1, specify the	Cost neutral
budget impact to the NHS as a whole.	Please specify:
X	Year 1: £0.00
	Year 2: £0.00
	Year 5: £0.00
C4.3 Where the budget impact is unknown set out the reasons why this cannot be measured	Not applicable

C4.4 Are there likely to be any costs or savings for non-NHS commissioners and/or public sector funders?	No Please specify: Click here to enter text.
C5 Funding	
C5.1 Where a cost pressure is indicated, state known source of funds for investment, where identified, e.g. decommissioning less clinically or cost-effective services.	As the position is to not routinely commission, there would not be a call upon the CPAG Prioritisation reserve.
C6 Financial Risks Associated with Implementing this Policy	
C6.1 What are the material financial risks to implementing this policy?	No material financial risks have been identified to implementing this policy
C6.2 How can these risks be mitigated?	Not applicable
C6.3 What scenarios (differential assumptions) have been explicitly tested to generate best case, worst case and most likely total cost scenarios?	Not applicable
C6.4 What scenario has been approved and why?	Not applicable
C7 Value for Money	

C7.1 What published evidence is available that the treatment is cost effective as evidenced in the evidence review?	There is no published evidence of cost-effectiveness  Please specify:  Click here to enter text.	
C7.2 Has other data been identified through the service	Select all that apply:	
specification development relevant to the assessment of value for money?	Available pricing data suggests the treatment is equivalent cost compared to current/comparator treatment	
	Available pricing data suggests the treatment is lower cost compared to current/comparator treatment	
	Available clinical practice data suggests the new treatment has the potential to improve value for money	
	Other data has been identified	
	No data has been identified	
	The data supports a high level of certainty about the impact on value	
	The data does not support a high level of certainty about the impact on value	
40	Please specify: Click here to enter text.	
C8 Cost Profile		
C8.1 Are there non-recurrent capital or revenue costs associated with this policy?	Choose an item.  If yes, specify type and range: Click here to enter text.	

C8.2 If yes, confirm the source of funds to meet these costs.	Click here to enter text.